Construction and prognostic value of enhanced CT image omics model for noninvasive prediction of HRG in bladder cancer based on logistic regression and support vector machine algorithm

Background Urothelial Carcinoma of the bladder (BLCA) is the most prevalent cancer of the urinary system. In cancer patients, HRG fusion is linked to a poor prognosis. The prediction of HRG expression by imaging omics in BLCA has not yet been fully investigated. Methods HRG expression in BLCA and healthy adjoining tissues was primarily identified utilizing data sourced from The Cancer Genome Atlas (TCGA). Using Kaplan–Meier survival curves and Landmark analysis, the relationship between HRG expression, clinicopathological parameters, and overall survival (OS) was investigated. Additionally, gene set variation analysis (GSVA) was conducted and CIBERSORTx was used to investigate the relationship between HRG expression and immune cell infiltration. The Cancer Imaging Archive (TCIA) provided CT images that were used for prognostic analysis, radiomic feature extraction, and construction of the model, respectively. The HRG expression levels were predicted using the constructed and evaluated LR and SMV models. Results HRG expression was shown to be substantially lower in BLCA tumors as opposed to that observed in normal tissues (p < 0.05). HRG expression had a close positive relationship with Eosinophils and a close negative relationship with B cells naive. The findings of the Landmark analysis illustrated that higher HRG was associated with improved patient survival at an early stage (P=0.048). The predictive performance of the two models, based on logistic regression analysis and support vector machine, was outstanding in the training and validation sets, yielding AUCs of 0.722 and 0.708, respectively, in the SVM model, and 0.727 and 0.662, respectively, in the LR.The models have good predictive efficiency. Conclusion HRG expression levels can have a significant impact on BLCA patients’ prognoses. The radiomic characteristics can successfully predict the pre-surgical HRG expression levels, based on CT- Image omics.

[1]  Liangren Liu,et al.  The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer , 2022, Frontiers in Immunology.

[2]  M. Fabritius,et al.  Accuracy and prognostic value of radiological lymph node features in variant histologies of bladder cancer , 2022, World Journal of Urology.

[3]  Minhong Wu,et al.  Prognostic Role of Pretreatment C-Reactive Protein to Albumin Ratio in Urological Cancers: A Systematic Review and Meta-Analysis , 2022, Frontiers in Oncology.

[4]  M. Ge,et al.  Radiomics signature for the prediction of progression-free survival and radiotherapeutic benefits in pediatric medulloblastoma , 2022, Child's Nervous System.

[5]  Huijie Jiang,et al.  A Potential Prognostic Marker for Recognizing VEGF-Positive Hepatocellular Carcinoma Based on Magnetic Resonance Radiomics Signature , 2022, Frontiers in Oncology.

[6]  Ş.M. Ertürk,et al.  Classification of retinoblastoma-1 gene mutation with machine learning-based models in bladder cancer , 2022, Heliyon.

[7]  Y. Lotan,et al.  Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy , 2022, Annals of Surgical Oncology.

[8]  Yan Zhao,et al.  Computed Tomography Radiomics-Based Prediction of Microvascular Invasion in Hepatocellular Carcinoma , 2022, Frontiers in Medicine.

[9]  X. Liu,et al.  CT-based radiomics for the preoperative prediction of the muscle-invasive status of bladder cancer and comparison to radiologists' assessment. , 2022, Clinical radiology.

[10]  M. Ladanyi,et al.  Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements , 2022, Cancer discovery.

[11]  K. Bar,et al.  Neutrophil-to-lymphocyte ratio as a predictor of overall survival and cancer advancement in patients undergoing radical cystectomy for bladder cancer , 2022, Central European journal of urology.

[12]  Tianyuan Xu,et al.  Magnetic resonance imaging-based radiomics signature for preoperative prediction of Ki67 expression in bladder cancer , 2021, Cancer Imaging.

[13]  Zhi-gang Yang,et al.  Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study , 2021, BMC cancer.

[14]  B. Hadaschik,et al.  The prognostic value of cytokeratin and extracellular collagen expression in urinary bladder cancer. , 2021, Current molecular medicine.

[15]  Hong Yang,et al.  Radiomics Analysis Based on Ultrasound Images to Distinguish the Tumor Stage and Pathological Grade of Bladder Cancer , 2021, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[16]  Lifang Wang,et al.  Targeting neuregulin 1 (NRG1): A novel biomarker for non-small-cell lung cancer , 2021, Journal of Environmental Pathology And Toxicology.

[17]  A. Lenis,et al.  Bladder Cancer: A Review. , 2020, JAMA.

[18]  Yuichi Sato,et al.  PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. , 2020, Urologic oncology.

[19]  C. Catalano,et al.  VI‐RADS for Bladder Cancer: Current Applications and Future Developments , 2020, Journal of magnetic resonance imaging : JMRI.

[20]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[21]  Q. Wei,et al.  Prognostic values of the clinicopathological characteristics and survival outcomes in micropapillary urothelial carcinoma of the bladder: A SEER database analysis , 2020, Cancer medicine.

[22]  C. Catalano,et al.  VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic , 2020, European Urology.

[23]  S. Ou,et al.  Neuregulin 1 Fusion-Positive NSCLC. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[25]  M. Wong,et al.  The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection , 2018, Scientific Reports.

[26]  E. Pleasance,et al.  Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  C. Corless,et al.  Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  D. Giannarelli,et al.  The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC) , 2017, Journal of Cancer Research and Clinical Oncology.

[29]  J. Witjes,et al.  MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .

[30]  Fredrik Y Frejd,et al.  Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds , 2016, mAbs.

[31]  W. Farhat,et al.  Role of Sonic Hedgehog (Shh) Signaling in Bladder Cancer Stemness and Tumorigenesis , 2016, Current Urology Reports.

[32]  Roman K. Thomas,et al.  Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer , 2014, Clinical Cancer Research.

[33]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[34]  R. Rodríguez-Barrueco,et al.  Neuregulins and Cancer , 2008, Clinical Cancer Research.

[35]  Douglas L Falls,et al.  Neuregulins: functions, forms, and signaling strategies. , 2003, Experimental cell research.

[36]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[37]  J. Affeldt,et al.  The feasibility study , 2019, The Information System Consultant’s Handbook.